ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

PHATHOM PHARMACEUTICALS, INC.

PHAT · NASDAQ

Medicinal and Botanical Manufacturing

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

Market Data

Price $11.11 +0.00 (+0.00%)
Market Cap$875M
P/E Ratio—
EPS$—
52W High$18.31
52W Low$2.21
Beta0.54

Data from Finnhub · Updated Mar 11, 2026

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.